01 — At a Glance
The Expensive Biotech Gamble That Hasn’t Landed Yet
- 52-Week High / Low₹425 / ₹295
- Q3 FY26 Revenue₹4,173 Cr
- Q3 FY26 PAT-₹52 Cr (Loss)
- Q3 FY26 EPS₹1.08
- TTM Full-Year EPS₹4.81
- Book Value₹200
- Price to Book1.95x
- Dividend Yield0.13%
- Debt / Equity0.62x
- BBL Integration₹5.5 Bn Valuation
Auditor’s Note: Biocon’s Q3 FY26 reads like a company in metamorphosis. Revenue at ₹4,173 crore (+9% YoY). Core EBITDA margin blooming to 29%. But reported PAT: a loss of ₹52 crore because of acquisition-related fair value adjustments and interest costs. The stock prices in a unicorn exit but delivers single-digit RoE and 6% ROCE. Biocon Biologics acquisition valued at $5.5 billion (~₹50,000 crore) is scheduled to close by March 2026. Two QIPs totalling ₹8,650 crore have been raised to fund it. The narrative is “high-growth pharma with global ambitions.” The valuation is “we believe you.”
02 — Introduction
Welcome to the Messiest Wealth Creation Story in Pharma
Biocon is a 46-year-old Indian biopharma company that set out to become a global innovator and has become a global acquirer instead. Founded in 1978 by Kiran Mazumdar Shaw (currently 44.91% promoter stake), it started as a biotech R&D shop and has metamorphosed into a three-legged beast: biosimilars (58% of revenue), generics (19%), and contract research services via Syngene (23%).
In December 2019, Biocon acquired the biosimilars business of Viatris for $1.2 billion — funded through a combination of debt and structured instruments. This single transaction tripled the ambition but also tripled the complexity. Jump to December 2025, and Biocon is now acquiring 100% of Biocon Biologics (the wholly-owned biosimilars JV) through a $5.5 billion all-in transaction. The deal involves a ₹4,150 crore QIP (already done in January 2026) and a second QIP of ₹4,500 crore planned for March 2026.
The concall in February 2026 dripped with ambition: interchangeable insulin biosimilars, GLP-1 generics in the US, oncology biosimilars against therapies representing a $75 billion market. The language was “Biocon 2.0” — a single integrated biopharma platform where “governance simplifies, capital allocation tightens, and cash flows consolidate.”
But here’s the kicker: despite all this, the company’s ROCE is 6.25%, ROE is 4.94% (3-year average), and the stock trades at 77.1x earnings. That’s not visionary. That’s a valuation asking the market to believe in a future that hasn’t been priced by the business’s current earning power. Let’s unhinge this carefully.
Concall Highlight (Feb 2026): “Future is more exciting than what the past has been.” Biocon management, essentially admitting the past 5 years have been rough. Honesty we can respect.
03 — Business Model: Three Legs, One Prayer
Biosimilars, Generics, and CRDMO Services Walk Into a Bar
Biocon operates three distinct revenue streams, each facing very different growth and return drivers.
Biosimilars (58% of FY25 revenue, growing +2–9% YoY): Through Biocon Biologics, the company manufactures and sells insulin biosimilars (Mylan partnership, now being acquired), monoclonal antibody biosimilars (trastuzumab, aflibercept, denosumab, ustekinumab), and newer oncology plays (nivolumab, pembrolizumab pending). Market is highly regulated (US, EU), price-competitive, and requires long clinical trials and FDA approvals. One approval delay = 18-24 month setbacks. Margin profile: 25–35% EBITDA when ramped (Q3 FY26: 28% margin at ₹2,497 crore revenue). Manufacturing happens in Malaysia (insulin), Bengaluru, and soon US (Cranbury). Top 5 global biosimilar player. US revenue: ~46–47% of biosimilars now.
Generics (19% of FY25 revenue, growing +8% YoY, +24% in Q3): APIs and formulations for off-patent small molecules. Biocon is betting aggressively on generic GLP-1 peptides (liraglutide launched EU, semaglutide in phase III). Also high-potency APIs (fermentation-based), complex injectables (Micafungin, Daptomycin pending US approvals). Lowest margin profile (5–10% EBITDA). Heavy capex burden (Vizag immunosuppressants facility, Bengaluru peptide facility). Management expects this to ramp post-2026 when facilities operationalise.
CRDMO via Syngene (23% of FY25 revenue, +4% YoY, -3% in Q3): Contract research, manufacturing for global pharma. 400+ active clients, 14 among top 20 global pharmas. High-margin (30%+), sticky, recurring. But Q3 saw headwinds: one large customer transition caused -3% YoY. Management called it transient.
Biosimilars Mix58%FY25 Revenue
Generics Mix19%FY25 Revenue
Research Mix23%FY25 Revenue
The Capex Trap: Biocon spent ~$275 million annually on capex between FY24–FY25 (Viatris acquisition integration + new facility builds). Management has signaled moderation to <$225 million, with further downside after Malaysia expands. But clinical trial costs for biosimilars R&D will remain elevated ($50–100M annually) for 4–5 years minimum.
💬 Which segment excites you most: insulin interchangeability in the US, or the generic GLP-1 bet? Comment your thesis.
04 — Financials Overview: Q3 FY26
The Numbers That Tell the Transformation Story (And Worry)
Result type: Quarterly Results | Q3 FY26 EPS: ₹1.08 | Annualised EPS (Q3×4): ₹4.32 | Full-year TTM EPS: ₹4.81
| Metric (₹ Cr) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 4,173 | 3,821 | 4,296 | +9.2% | -2.9% |
| EBITDA (Reported) | 951 | 784 | 835 | +21.3% | +13.9% |
| EBITDA Margin % | 22.8% | 20.5% | 19.4% | +230 bps | +340 bps |
| Core EBITDA | 1,221 | 1,010 | 1,081 | +20.8% | +13.0% |
| Core EBITDA Margin % | 29.0% | 26.4% | 25.2% | +260 bps | +380 bps |
| PAT (Reported) | -52 | 81 | 133 | Loss | -139% |
| EPS (₹) | 1.08 | 0.21 | 0.63 | +414% | +71.4% |
Translation: Q3 reported PAT is a loss because of one-off fair value adjustments on the Biocon Biologics acquisition ($40 million charge) and elevated interest costs (~₹210 crore from debt). Strip those out, and core operating profit is healthier. Core EBITDA +21% YoY is solid. But the reported loss makes the P/E calculation complex — we’re using trailing twelve months (TTM) EPS of ₹4.81 for actual P/E 77.1x. The annualised EPS from Q3 alone (₹1.08 × 4 = ₹4.32) underestimates true earning power post-integration. Patience required.
05 — Valuation: Fair Value Range
What’s a Biotech Company Worth When It Hasn’t Delivered Yet?
Join 10,000+ investors who read this every week.
